Acadia Pharma Q3 net loss narrows to $0.09/shr; NUPLAZID sales up 9% to $131.6M

ACADIA PHARMACEUTICALS INC

2022-Q3 EPS reported -$0.78 revenue$131,612,000

Net loss per share of $0.09, improved from $0.54 loss in Q3 2020; revenue $131.6M (+9% YoY).
2021 NUPLAZID sales guidance narrowed to $480M-$500M from $480M-$515M; R&D guidance lowered.
FDA meeting scheduled to discuss pimavanserin sNDA resubmission for dementia-related psychosis subgroups.
Top-line results expected Q4 2021 for trofinetide (Rett syndrome) and Q1 2022 for ACP-044 (pain).
Promoted Brendan Teehan to EVP, COO, Head of Commercial; Julie Fisher to SVP, Marketing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.